These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 33938701

  • 1. Vismodegib as Eye-Sparing Neoadjuvant Treatment for Locally Advanced Periocular Basal Cell Carcinoma.
    Angnardo L, Humeda Y, Alexandraki I, Wolfe CM, Cognetta AB.
    J Drugs Dermatol; 2021 May 01; 20(5):552-554. PubMed ID: 33938701
    [Abstract] [Full Text] [Related]

  • 2. Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma.
    Sagiv O, Nagarajan P, Ferrarotto R, Kandl TJ, Thakar SD, Glisson BS, Altan M, Esmaeli B.
    Br J Ophthalmol; 2019 Jun 01; 103(6):775-780. PubMed ID: 30021814
    [Abstract] [Full Text] [Related]

  • 3. Neoadjuvant Vismodegib and Mohs Micrographic Surgery for Locally Advanced Periocular Basal Cell Carcinoma.
    González AR, Etchichury D, Gil ME, Del Aguila R.
    Ophthalmic Plast Reconstr Surg; 2019 Jun 01; 35(1):56-61. PubMed ID: 30444747
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Vismodegib for periocular and orbital basal cell carcinoma.
    Gill HS, Moscato EE, Chang AL, Soon S, Silkiss RZ.
    JAMA Ophthalmol; 2013 Dec 01; 131(12):1591-4. PubMed ID: 24136169
    [Abstract] [Full Text] [Related]

  • 6. A randomized phase II study evaluating vismodegib as neoadjuvant treatment of basal cell carcinoma preceding Mohs micrographic surgery: results and lessons learned.
    Soon SL, Ibrahim SF, Arron ST.
    Br J Dermatol; 2019 Jul 01; 181(1):208-209. PubMed ID: 30628055
    [No Abstract] [Full Text] [Related]

  • 7. Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma.
    Alcalay J, Tauber G, Fenig E, Hodak E.
    J Drugs Dermatol; 2015 Mar 01; 14(3):219-23. PubMed ID: 25738842
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.
    Demirci H, Worden F, Nelson CC, Elner VM, Kahana A.
    Ophthalmic Plast Reconstr Surg; 2015 Mar 01; 31(6):463-6. PubMed ID: 25675162
    [Abstract] [Full Text] [Related]

  • 9. Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial.
    Ben Ishai M, Tiosano A, Fenig E, Ben Simon G, Yassur I.
    JAMA Ophthalmol; 2020 Jul 01; 138(7):749-755. PubMed ID: 32407451
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Secondary Resistance to Vismodegib After Initial Successful Treatment of Extensive Recurrent Periocular Basal Cell Carcinoma with Orbital Invasion.
    Papastefanou VP, René C.
    Ophthalmic Plast Reconstr Surg; 2017 Jul 01; 33(3S Suppl 1):S68-S70. PubMed ID: 26398246
    [Abstract] [Full Text] [Related]

  • 13. Management of periorbital basal cell carcinoma with orbital invasion.
    Sun MT, Wu A, Figueira E, Huilgol S, Selva D.
    Future Oncol; 2015 Nov 01; 11(22):3003-10. PubMed ID: 26437207
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Two different scenarios of advanced basal cell carcinomas during the use of vismodegib: Cases of oral administration and administration directly to the stomach.
    Rodríguez-Cerdeira C, Muñoz-Garzón V, González-Cespón JL.
    Drug Discov Ther; 2019 Nov 01; 13(2):122-127. PubMed ID: 31080204
    [Abstract] [Full Text] [Related]

  • 16. Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.
    Pollom EL, Bui TT, Chang AL, Colevas AD, Hara WY.
    JAMA Dermatol; 2015 Sep 01; 151(9):998-1001. PubMed ID: 25874733
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of Vismodegib for the Treatment of Orbital and Advanced Periocular Basal Cell Carcinoma.
    Eiger-Moscovich M, Reich E, Tauber G, Berliner O, Priel A, Ben Simon G, Elkader AA, Yassur I.
    Am J Ophthalmol; 2019 Nov 01; 207():62-70. PubMed ID: 31077664
    [Abstract] [Full Text] [Related]

  • 18. Identifying patients at risk for recurrent or advanced BCC.
    Hamid O, Goldenberg G.
    J Drugs Dermatol; 2013 Nov 01; 12(11):1246-52; quiz 1253-4. PubMed ID: 24196332
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.